The combination of strong revenue growth, improving financial position, and multiple near-term catalysts (PDUFA decision, topline data readouts) creates a favorable risk-reward profile. Traders should monitor the March 20 FDA decision on setmelanotide for acquired HO as a potential significant upside catalyst.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $98.07entry
- T+1 · 9mo ago −5.45%α −4.99% · $92.73
- T+5 · 9mo ago −6.74%α −5.61% · $91.46
- T+20 · 8mo ago −16.49%α −10.09% · $81.90
- T+60 · 6mo ago −8.04%α −15.79% · $90.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, with Q4 net product revenue of $57.3 million, representing 12% sequential growth and 37% year-over-year growth. The company also highlighted key clinical progress, including a positive end-of-Phase-2 meeting with the FDA for bivamelagon and upcoming PDUFA decision for setmelanotide in acquired hypothalamic obesity on March 20, 2026. Cash position increased to $388.9 million, providing funding for at least 24 months.
Key Financial Metrics
Key Facts
- Q4 2025 net product revenue was $57.3 million, up 12% sequentially and 37% year-over-year from $41.8 million in Q4 2024
- Full year 2025 revenue was $194.8 million, up 50% from $130.1 million in 2024
- Net loss attributable to common stockholders was $48.8 million in Q4 2025, improved from $44.6 million in Q4 2024
- Cash, cash equivalents and short-term investments were $388.9 million as of December 31, 2025, up from $320.6 million as of December 31, 2024
- FDA PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity is March 20, 2026
- Company expects to initiate Phase 3 trial for bivamelagon in acquired HO by year-end 2026
Financial Impact
Revenue grew 37% year-over-year in Q4 and 50% for the full year, while cash position increased by $68.3 million year-over-year
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| IMCIVREE | $194.8M | +49.7% |
Risk Factors
- FDA may not approve setmelanotide for acquired hypothalamic obesity indication
- Upcoming clinical trial data readouts in March 2026 could be disappointing
- Operating expenses are expected to increase significantly in 2026 ($385M-$415M non-GAAP)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011987 |
| Document: 0001628280-26-011987-index.html | 0001628280-26-011987 |
| Document: 0001628280-26-011987.txt | 0001628280-26-011987 |
Track record
26 reports on RYTM
9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers